


16E1  
PATENT  
Atty. Docket No. 1155.005



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Douglas J. Jolly et al.

Serial No.: 09/001,039

Group Art Unit: to be assigned

Filed : December 30, 1997

Examiner: to be assigned

For :

METHODS FOR ADMINISTRATION OF RECOMBINANT  
GENE DELIVERY VEHICLES FOR TREATMENT OF  
HEMOPHILIA AND OTHER DISORDERS

#6  
IDS  
8-20-98  
KD

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56 AND §1.97(b)(3)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

MAY 26 1998

Sir:

The citations listed on the enclosed Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(b)(3). The Examiner is requested to make these citations of official record in the present application.

Also enclosed herewith is a copy of the International Search Report for PCT International Application No. PCT/US95/16852.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.


This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(b)(3) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

I hereby certify that this correspondence  
being deposited with the United States Postal  
Service as First Class mail in an envelope  
addressed to: Commissioner of Patents and  
Trademarks, Washington, D.C. 20231, on  
this 9 day of Feb., 1998  
By [Signature]

The Commissioner is hereby authorized to charge any fees in connection with this Information Disclosure Statement to Deposit Account No. 03-1664. This, however, is not an authorization for payment of issue fee.


Respectfully submitted,

By:

  
Norman J. Kruse, Ph.D.  
Attorney for Applicants  
Reg. No. 35,235

February 9, 1998

CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, California 94662-8097  
(510) 923-3520  
(510) 655-3542 (fax)



FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1155.005	Serial No.: 09/001,039
INFORMATION		Applicants: Jolly <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: December 30, 1997	Group: to be assigned

## U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	5,512,421	04/30/96	Burnes <u>et al.</u>	435	320.1	08/10/93
	AB	4,861,719	08/29/89	Miller	435	236	04/25/86
	AC	5,691,177	11/25/97	Gruber <u>et al.</u>	435	172.3	06/05/95
	AD	5,328,470	07/12/94	Nabel <u>et al.</u>	604	101	07/26/91

## FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans-Yes	lation No
	BA	WO 95/34669	12/21/95	PCT				
	BB	WO 94/29440	12/22/94	PCT				
	BC	WO 94/29471	12/22/94	PCT				
	BD	WO 96/21014	07/11/96	PCT				
	BE	WO 92/07943	05/14/92	PCT				
	BF	WO 93/25698	12/23/93	PCT				
	BG	WO 95/27512	10/19/95	PCT				
	BH	WO 90/08771	08/09/90	PCT				
	BI	260,148	03/16/88	Europe				

## OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Connolly <u>et al.</u> , "In Vivo Gene Delivery and Expression of Physiological Levels of Functional Human Factor VIII in Mice" <u>Human Gene Therapy</u> 6:185-192, February, 1995
CB	Connolly <u>et al.</u> , "High Level Tissue-Specific Expression of Functional Human Factor VIII in Mice" <u>Human Gene Therapy</u> 7:183-195, January, 1996
CC	Connolly <u>et al.</u> , "Complete Short-Term Correction of Canine Hemophilia A by In Vivo Gene Therapy" <u>Blood</u> 88(10):3846-3853, 1996
CD	Connolly <u>et al.</u> , "Sustained Expression of Therapeutic Levels of Human Factor VIII in Mice" <u>Blood</u> 87(11):4671-4677, 1996
CE	Dwarki <u>et al.</u> , "Gene Therapy for Hemophilia A: Production of Therapeutic Levels of Human Factor VIII in vivo in Mice" <u>Proc. Natl. Acad. Sci.</u> 92:1023-1027, February, 1995
CF	Gorgas and Krisans, "Zonal Heterogeneity of Peroxisome Proliferation and Morphology in rat Liver After Gemfibrozil Treatment" <u>J. Lipid Research</u> 30:1859-1875, 1989
CG	Hoeben <u>et al.</u> , "Toward Gene Therapy for Hemophilia A: Long-Term Persistence of Factor VIII-Secreting Fibroblasts after Transplantation into Immunodeficient Mice" <u>Human Gene Therapy</u> 4:179-186, 1993
CH	Hoeben <u>et al.</u> , "Toward Gene Therapy in Haemophilia A: Retrovirus-Mediated Transfer of a Factor VIII Gene into Murine Haematopoietic Progenitor Cells" <u>Thrombosis and Haemostasis</u> 67(3):341-345, 1992
CI	Issemann and Green, "Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferators" <u>Nature</u> 347:645-650, October, 1990
CJ	Izumi <u>et al.</u> , "Induction of Hepatic Ornithine Decarboxylase by Hypolipidemic Drugs with Hepatic Peroxisome Proliferative Activity" <u>Carcinogenesis</u> 2(7):623-627, 1981
CK	Joplin <u>et al.</u> , "Human Intrahepatic Biliary Epithelial Cells Proliferate in Vitro in Response to Human Hepatocyte Growth Factor" <u>J. Clin. Invest.</u> 90:1284-1289, October, 1992
CL	Kakei <u>et al.</u> , "Effects of Long-Term Omeprazole Treatment on Adult Rat Gastric Mucosa-Enhancement of the Epithelial Cell Proliferation and Suppression of its Differentiation" <u>Biochemical and Biophysical Research Communications</u> 214(3):861-868, September, 1995
Examiner	Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1155.005	Serial No.: 09/001,039
INFORMATION DISCLOSURE CITATION		Applicant: Jolly et al.	
(Use several sheets if necessary)		Filing Date: December 30, 1997	Group:

## OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

CM	Liu et al., "Collagenase Pretreatment and the Mitogenic Effects of Hepatocyte Growth Factor and Transforming Growth Factor- $\alpha$ in Adult Rat Liver" <u>Hepatology</u> 19(6):1521-1527, 1994
CN	Lundgren et al., "Effects of Dietary Treatment with Clofibrate, Nafenopin or WY-14.643 on Mitochondria and DNA in Mouse Liver" <u>Biochimica et Biophysica Acta</u> 1035:132-138, 1990
CO	Mars et al., "Activation of Hepatocyte Growth Factor by the Plasminogen Activators uPA and tPA" <u>American Journal of Pathology</u> 143(3):949-958, September, 1993
CP	Mead et al., "Induction of Replicative Competence ("Priming") in Normal Liver" <u>Cancer Research</u> 50:7023-7030, November, 1990
CQ	Miller et al., "Compact Organization of the Hepatitis B Virus Genome" <u>Hepatology</u> 9(2):322-327, 1989
CR	Mizuno et al., "Purification and Characterization of Hepatocyte Growth Factor (HGF)-Converting Enzyme: Activation of Pro-HGF" <u>Biochemical and Biophysical Research Communications</u> 198(3):1161-1169, February, 1994
CS	Moscioni et al., "In vivo Regional Delivery of Retrovirally Mediated Foreign Genes to rat Liver Cells: Need for Partial Hepatectomy for Successful Foreign Gene Expression" <u>Surgery</u> 113(3):304-311, March, 1993
CT	Motojima and Goto, "Rat Liver BiP/GRP78 is Down-Regulated by a Peroxisome-Proliferator, Clofibrate" <u>FEBS</u> 308(2):207-210, August, 1992
CU	Ohmura et al., "Hepatocyte Proliferation Induced by a Single Dose of a Peroxisome Proliferator" <u>American J. Pathology</u> 148(3):815-824, March, 1996
CV	Reddy et al., "Carcinogenesis by Hepatic Peroxisome Proliferators: Evaluation of the Risk of Hypolipidemic Drugs and Industrial Plasticizers to Humans" <u>CRC Critical Reviews in Toxicology</u> 12(1):1-58, 1983
CW	Rettinger et al., "Liver-Directed Gene Therapy: Quantitative Evaluation of Promoter Elements by using in vivo Retroviral Transduction" <u>Proc. Natl. Acad. Sci. USA</u> 91:1460-1464, February, 1994
CX	Roberts et al., "Non-Genotoxic Hepatocarcinogens Stimulate DNA Synthesis and Their Withdrawal Induces Apoptosis, but in Different Hepatocyte Populations" <u>Carcinogenesis</u> 16(8):1693-1698, 1995
CY	Sausen et al., "Gemfibrozil-Induced Peroxisome Proliferation and Hepatomegaly in Male F344 Rats" <u>Cancer Letters</u> 97:263-268, 1995
CZ	Schechter et al., "The new Oncogene: an <i>erb-B</i> -related Gene Encoding a 185,000-M <sub>r</sub> Tumour Antigen" <u>Nature</u> 312:513-516, December, 1984
C1	Shih et al., "Transforming Genes of Carcinomas and Neuroblastomas Introduced into Mouse Fibroblasts" <u>Nature</u> 290:261-264, March, 1981
C2	Shimomura et al., "Activation of Hepatocyte Growth Factor by Two Homologous Proteases, Blood-Coagulation Factor XIIa and hepatocyte Growth Factor Activator" <u>Eur. J. Biochem.</u> 229:257-261, 1995
C3	Shimomura et al., "A Novel Protease Obtained from FBS-Containing Culture Supernatant, that Processes Single Chain form Hepatocyte Growth Factor to Two Chain form in Serum-Free Culture" <u>Cytotechnology</u> 8:219-229, 1992
C4	Slamon et al., "Studies of the <i>HER-2/neu</i> Proto-Oncogene in Human Breast Cancer" <u>Cancer Cells</u> 7:371-384, 1989
C5	Uribe, "Indomethacin Accelerates Clearance of Labeled Cells and Increases DNA Synthesis in Gastrointestinal Mucosa of the Rat" <u>Digestive Diseases and Sciences</u> 37(3):403-408, March, 1992
C6	Zatloukal et al., "In vivo Production of Human Factor VIII in Mice After Intrasplenic Implantation of Primary Fibroblasts Transfected by Receptor-Mediated, Adenovirus-Augmented Gene Delivery" <u>Proc. Natl. Acad. Sci. USA</u> 91:5148-5152, May, 1994
C7	Archer et al., "Human Growth Hormone (hGH) Secretion in Milk of Goats After Direct Transfer of the hGH Gene into the Mammary Gland by Using Replication-Defective Retrovirus Vectors" <u>Proc. Natl. Acad. Sci. USA</u> 91:6840-6844, July, 1994
Examiner	
Date Considered	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1155.005	Serial No.: 09/001,039
INFORMATION DISCLOSURE CITATION		Applicant: Jolly <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: December 30, 1997	Group:

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

[illegible]

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.